Burden of cancers in India - estimates of cancer crude incidence, YLLs, YLDs and DALYs for 2021 and 2025 based on National Cancer Registry Program.


Journal

BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800

Informations de publication

Date de publication:
11 May 2022
Historique:
received: 12 06 2021
accepted: 14 04 2022
entrez: 13 5 2022
pubmed: 14 5 2022
medline: 18 5 2022
Statut: epublish

Résumé

Cancer is the major cause of morbidity and mortality worldwide. The cancer burden varies within the regions of India posing great challenges in its prevention and control. The national burden assessment remains as a task which relies on statistical models in many developing countries, including India, due to cancer not being a notifiable disease. This study quantifies the cancer burden in India for 2016, adjusted mortality to incidence (AMI) ratio and projections for 2021 and 2025 from the National Cancer Registry Program (NCRP) and other publicly available data sources. Primary data on cancer incidence and mortality between 2012 and 2016 from 28 Population Based Cancer Registries (PBCRs), all-cause mortality from Sample Registration Systems (SRS) 2012-16, lifetables and disability weight from World Health Organization (WHO), the population from Census of India and cancer prevalence using the WHO-DisMod-II tool were used for this study. The AMI ratio was estimated using the Markov Chain Monte Carlo method from longitudinal NCRP-PBCR data (2001-16). The burden was quantified at national and sub-national levels as crude incidence, mortality, Years of Life Lost (YLLs), Years Lived with Disability (YLDs) and Disability Adjusted Life Years (DALYs). The projections for the years 2021 and 2025 were done by the negative binomial regression model using STATA. The projected cancer burden in India for 2021 was 26.7 million DALYs This study demonstrates the use of reliable data sources and DisMod-II tools that adhere to the international standard for assessment of national and sub-national cancer burden. A wide heterogeneity in leading cancer sites was observed within India by age and sex. The results also highlight the need to focus on non-leading sites of cancer by age and sex. These findings can guide policymakers to plan focused approaches towards monitoring efforts on cancer prevention and control. The study simplifies the methodology used for arriving at the burden estimates and thus, encourages researchers across the world to take up similar assessments with the available data.

Sections du résumé

BACKGROUND BACKGROUND
Cancer is the major cause of morbidity and mortality worldwide. The cancer burden varies within the regions of India posing great challenges in its prevention and control. The national burden assessment remains as a task which relies on statistical models in many developing countries, including India, due to cancer not being a notifiable disease. This study quantifies the cancer burden in India for 2016, adjusted mortality to incidence (AMI) ratio and projections for 2021 and 2025 from the National Cancer Registry Program (NCRP) and other publicly available data sources.
METHODS METHODS
Primary data on cancer incidence and mortality between 2012 and 2016 from 28 Population Based Cancer Registries (PBCRs), all-cause mortality from Sample Registration Systems (SRS) 2012-16, lifetables and disability weight from World Health Organization (WHO), the population from Census of India and cancer prevalence using the WHO-DisMod-II tool were used for this study. The AMI ratio was estimated using the Markov Chain Monte Carlo method from longitudinal NCRP-PBCR data (2001-16). The burden was quantified at national and sub-national levels as crude incidence, mortality, Years of Life Lost (YLLs), Years Lived with Disability (YLDs) and Disability Adjusted Life Years (DALYs). The projections for the years 2021 and 2025 were done by the negative binomial regression model using STATA.
RESULTS RESULTS
The projected cancer burden in India for 2021 was 26.7 million DALYs
CONCLUSIONS CONCLUSIONS
This study demonstrates the use of reliable data sources and DisMod-II tools that adhere to the international standard for assessment of national and sub-national cancer burden. A wide heterogeneity in leading cancer sites was observed within India by age and sex. The results also highlight the need to focus on non-leading sites of cancer by age and sex. These findings can guide policymakers to plan focused approaches towards monitoring efforts on cancer prevention and control. The study simplifies the methodology used for arriving at the burden estimates and thus, encourages researchers across the world to take up similar assessments with the available data.

Identifiants

pubmed: 35546232
doi: 10.1186/s12885-022-09578-1
pii: 10.1186/s12885-022-09578-1
pmc: PMC9092762
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

527

Informations de copyright

© 2022. The Author(s).

Références

JCO Glob Oncol. 2020 Jul;6:1063-1075
pubmed: 32673076
JAMA. 2001 Feb 7;285(5):535-9
pubmed: 11176854
Asian Pac J Cancer Prev. 2010;11(3):633-40
pubmed: 21039029
Lancet Oncol. 2018 Oct;19(10):1289-1306
pubmed: 30219626
JAMA Oncol. 2018 Nov 1;4(11):1553-1568
pubmed: 29860482
J Glob Oncol. 2019 Jul;5:1-15
pubmed: 31373840
Popul Health Metr. 2003 Apr 14;1(1):4
pubmed: 12773212
Lancet. 2017 Dec 2;390(10111):2437-2460
pubmed: 29150201
Environ Health Perspect. 1983 Apr;50:329-38
pubmed: 6873023
Arch Public Health. 2020 Aug 24;78:77
pubmed: 32850124
Int J Epidemiol. 2015 Oct;44(5):1657-9
pubmed: 26320032
Lancet Oncol. 2014 May;15(6):e205-12
pubmed: 24731885
Eur J Cancer. 2009 Mar;45(5):756-64
pubmed: 19128954
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Lancet Glob Health. 2019 Dec;7(12):e1675-e1684
pubmed: 31708148
Bull World Health Organ. 2002;80(8):611
pubmed: 12219149

Auteurs

Vaitheeswaran Kulothungan (V)

Indian Council Medical Research (ICMR) - National Centre for Disease Informatics and Research (NCDIR), Nirmal Bhawan-ICMR Complex (II Floor), Poojanahalli, Kannamangala Post, Bengaluru, Karnataka, 562 110, India.

Krishnan Sathishkumar (K)

Indian Council Medical Research (ICMR) - National Centre for Disease Informatics and Research (NCDIR), Nirmal Bhawan-ICMR Complex (II Floor), Poojanahalli, Kannamangala Post, Bengaluru, Karnataka, 562 110, India.

Sravya Leburu (S)

Indian Council Medical Research (ICMR) - National Centre for Disease Informatics and Research (NCDIR), Nirmal Bhawan-ICMR Complex (II Floor), Poojanahalli, Kannamangala Post, Bengaluru, Karnataka, 562 110, India.

Thilagavathi Ramamoorthy (T)

Indian Council Medical Research (ICMR) - National Centre for Disease Informatics and Research (NCDIR), Nirmal Bhawan-ICMR Complex (II Floor), Poojanahalli, Kannamangala Post, Bengaluru, Karnataka, 562 110, India.

Santhappan Stephen (S)

Indian Council Medical Research (ICMR) - National Centre for Disease Informatics and Research (NCDIR), Nirmal Bhawan-ICMR Complex (II Floor), Poojanahalli, Kannamangala Post, Bengaluru, Karnataka, 562 110, India.

Dharmappa Basavarajappa (D)

National Health Mission, Bengaluru, Karnataka, India.

Nifty Tomy (N)

Indian Council Medical Research (ICMR) - National Centre for Disease Informatics and Research (NCDIR), Nirmal Bhawan-ICMR Complex (II Floor), Poojanahalli, Kannamangala Post, Bengaluru, Karnataka, 562 110, India.

Rohith Mohan (R)

Indian Council Medical Research (ICMR) - National Centre for Disease Informatics and Research (NCDIR), Nirmal Bhawan-ICMR Complex (II Floor), Poojanahalli, Kannamangala Post, Bengaluru, Karnataka, 562 110, India.

Geetha R Menon (GR)

Indian Council Medical Research (ICMR) - National Institute of Medical Statistics (NIMS), New Delhi, India.

Prashant Mathur (P)

Indian Council Medical Research (ICMR) - National Centre for Disease Informatics and Research (NCDIR), Nirmal Bhawan-ICMR Complex (II Floor), Poojanahalli, Kannamangala Post, Bengaluru, Karnataka, 562 110, India. ncdir@ncdirindia.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH